China NT Pharma Group Company Limited (HKG:1011)
Hong Kong · Delayed Price · Currency is HKD 0.4000
-0.0050 (-1.23%)
Aug 26, 2026, 3:32 PM HKT
HKG:1011 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 35.83 | 24.16 | 37.96 | 7.37 | - | 226.7 | |
Revenue Growth | 92.03% | -36.36% | 415.34% | - | - | 2.24% |
Cost of Revenue | 29.28 | 14.55 | 32.7 | - | - | 81.24 |
Gross Profit | 6.55 | 9.61 | 5.26 | 7.37 | - | 145.46 |
Selling, General & Admin | 20.41 | 21.97 | 18.49 | 63.57 | 22.62 | 229.19 |
Operating Expenses | 20.41 | 21.97 | 18.49 | 63.57 | 26.54 | 238.93 |
Operating Income | -13.87 | -12.36 | -13.23 | -56.21 | -26.54 | -93.47 |
Interest Expense | -26.09 | -27.84 | -31.54 | -28.82 | -39.37 | -88.73 |
Interest & Investment Income | 0 | 0.01 | 0.01 | 0.01 | 0.04 | 0.24 |
Earnings From Equity Investments | - | - | 10.24 | 37.04 | 9 | 34.49 |
Currency Exchange Gain (Loss) | - | - | - | - | - | 6.66 |
Other Non Operating Income (Expenses) | 0.28 | 0.01 | 0.23 | 0.26 | 0.5 | 6.5 |
EBT Excluding Unusual Items | -39.67 | -40.19 | -34.28 | -47.71 | -56.37 | -134.32 |
Merger & Restructuring Charges | - | - | - | - | - | -1.4 |
Gain (Loss) on Sale of Investments | 13.93 | 14.08 | -5.92 | - | -0.63 | -6.04 |
Gain (Loss) on Sale of Assets | - | - | -7.01 | 12.29 | - | 41.04 |
Legal Settlements | - | - | - | - | - | -40.63 |
Other Unusual Items | -0.14 | -0.14 | -6.27 | 2.05 | 6.95 | -7.4 |
Pretax Income | -25.89 | -26.26 | -53.48 | -33.37 | -50.04 | -148.75 |
Income Tax Expense | - | - | -0.12 | 0.12 | - | 2.58 |
Earnings From Continuing Operations | -25.89 | -26.26 | -53.36 | -33.49 | -50.04 | -151.33 |
Earnings From Discontinued Operations | - | - | - | -110.1 | -16.37 | - |
Net Income to Company | -25.89 | -26.26 | -53.36 | -143.59 | -66.41 | -151.33 |
Minority Interest in Earnings | -1.68 | 0.21 | - | - | - | 1.8 |
Net Income | -27.57 | -26.04 | -53.36 | -143.59 | -66.41 | -149.54 |
Net Income to Common | -27.57 | -26.04 | -53.36 | -143.59 | -66.41 | -149.54 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 748 | 617 | 264 | 239 | 190 | 189 |
Shares Outstanding (Diluted) | 748 | 617 | 264 | 239 | 190 | 189 |
Shares Change | 81.91% | 133.61% | 10.72% | 25.59% | 0.51% | 0.14% |
EPS (Basic) | -0.04 | -0.04 | -0.20 | -0.60 | -0.35 | -0.79 |
EPS (Diluted) | -0.04 | -0.04 | -0.20 | -0.60 | -0.35 | -0.79 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -5.55 | -9.24 | 39.74 | 31.72 | -135.98 |
Free Cash Flow Per Share | - | -0.01 | -0.04 | 0.17 | 0.17 | -0.72 |
Gross Margin | 18.27% | 39.78% | 13.86% | 100.00% | - | 64.16% |
Operating Margin | -38.70% | -51.18% | -34.84% | -763.07% | - | -41.23% |
Profit Margin | -76.94% | -107.80% | -140.56% | -1949.36% | - | -65.96% |
Free Cash Flow Margin | - | -22.96% | -24.35% | 539.55% | - | -59.98% |
EBITDA | -13.8 | -12.31 | -13.18 | -51.63 | -9.39 | -57.27 |
EBITDA Margin | -38.51% | -50.97% | -34.72% | - | - | -25.26% |
D&A For EBITDA | 0.07 | 0.05 | 0.05 | 4.58 | 17.16 | 36.2 |
EBIT | -13.87 | -12.36 | -13.23 | -56.21 | -26.54 | -93.47 |
EBIT Margin | -38.70% | -51.18% | -34.84% | - | - | -41.23% |
Advertising Expenses | - | 4.89 | - | - | - | 141.48 |